CureVac signs manufacturing agreement with Novartis for COVID-19 vaccine candidate
German biopharma company CureVac has signed an initial manufacturing agreement with Novartis for its COVID-19 vaccine candidate CVnCoV.
When the agreement is finalised, Novartis plans to manufacture the mRNA and bulk drug product of CureVac's CVnCoV for up to 50 million doses by the end of 2021, with further scale-up to 200 million doses in 2022.
Deliveries of the CVnCoV doses from Novartis’ Kundl, Austria manufacturing site are expected to begin in summer 2021.
"We feel it is our responsibility to do everything in our power to help and we are pleased to announce our collaboration with CureVac,” said Steffen Lang, global head of Novartis technical operations and member of the executive committee, Novartis.
Read more: http://www.pmlive.com/pharma_news/curevac_signs_manufacturing_agreement_with_novartis_for_covid-19_vaccine_candidate_1364625
When the agreement is finalised, Novartis plans to manufacture the mRNA and bulk drug product of CureVac's CVnCoV for up to 50 million doses by the end of 2021, with further scale-up to 200 million doses in 2022.
Deliveries of the CVnCoV doses from Novartis’ Kundl, Austria manufacturing site are expected to begin in summer 2021.
"We feel it is our responsibility to do everything in our power to help and we are pleased to announce our collaboration with CureVac,” said Steffen Lang, global head of Novartis technical operations and member of the executive committee, Novartis.
Read more: http://www.pmlive.com/pharma_news/curevac_signs_manufacturing_agreement_with_novartis_for_covid-19_vaccine_candidate_1364625
